India’s Pharmaceutical Supply Chain Gains Global Momentum

India’s Pharmaceutical Supply Chain Gains Global Momentum

India is emerging as a key player in the global pharmaceutical supply chain, with its Contract Research, Development, and Manufacturing Organization (CRDMO) industry poised for remarkable growth. According to a recent Macquarie Equity Research report, the industry is projected to expand from approximately USD 7 billion to USD 14 billion by 2028, driven by increasing pharmaceutical outsourcing, regulatory support, and supply chain diversification.

India’s cost advantages, skilled workforce, and regulatory excellence make it an attractive destination for global pharmaceutical firms seeking reliable and efficient partners. The report highlights that favorable policies, such as the US Biosecure Act, could further accelerate this growth, potentially pushing the sector to USD 22 billion by 2030.

With a strong reputation for high-quality Active Pharmaceutical Ingredients (APIs), Highly Potent APIs (HPAPIs), and specialty chemicals, India is strengthening its role in the global supply chain. As companies worldwide look to optimize costs and reduce dependency on single-source suppliers, India presents itself as a trusted, innovative, and cost-effective solution for pharmaceutical manufacturing and development.

This positive outlook underscores India’s expanding influence in global pharmaceutical logistics, reinforcing its position as a critical hub for supply chain efficiency, regulatory compliance, and sustainable growth.

#ICTTMNews #BreakingNews #PharmaceuticalSupplyChain #GlobalTrade #SupplyChainResilience #PharmaLogistics #IndiaManufacturing